Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention

Graft-versus-host Disease Clinical Trial

Official title:

A Phase IB-II Study Of High-Dose Post-Transplant Cyclophosphamide, Abatacept, and Short-Duration Tacrolimus for the Prevention of Graft-Versus-Host Disease (GvHD) Following Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04503616
• Other study ID #: 20-00136
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: September 16, 2020
• Est. completion date: June 20, 2024

Study information

• Verified date: February 2024
• Source: NYU Langone Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single arm, open label, optimal 2-stage Simon design phase Ib-II clinical trial. Adult patients with hematological malignancies undergoing allogeneic HSCT from first- or second-degree haploidentical donor are eligible for the study if they meet the standard criteria defined in our institutional standard operation procedures (SOPs), meet all inclusion criteria, and do not satisfy any exclusion criteria. Patients will receive non-myeloablative, reduced-intensity or myeloablative conditioning regimen followed by peripheral blood hematopoietic stem cells. Patients will receive cyclophosphamide, abatacept, and short-duration tacrolimus for GvHD prophylaxis.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 46
• Est. completion date: June 20, 2024
• Est. primary completion date: December 14, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18 years

2. Karnofsky score = 70%

3. No evidence of progressive bacterial, viral, or fungal infection

4. Creatinine clearance > 50 mL/min/1.72m2

5. Total bilirubin, ALT and AST < 2 x the upper limit of normal (except for diagnosed Gilbert's syndrome)

6. Alkaline phosphatase = 250 IU/L

7. Left Ventricular Ejection Fraction (LVEF) > 45%

8. Adjusted Carbon Monoxide Diffusing Capacity (DLCO) > 60%

9. Negative HIV serology

10. Negative pregnancy test: confirmation per negative serum ß-human chorionic gonadotropin (ß-hCG) for women of childbearing age and potential.

Exclusion Criteria:

1. Donors are excluded in case of donor-specific HLA antibodies or positive cross-match.

2. Pregnant or nursing females or women of child bearing age or potential, who are unwilling to completely abstain from heterosexual sex or practice 2 effective methods of contraception from the first dose of conditioning regimen through day +180. A woman of reproductive capability is one who has not undergone a hysterectomy (removal of the womb), has not had both ovaries removed, or has not been post-menopausal (stopped menstrual periods) for more than 24 months in a row.

3. Male subjects who refuse to practice effective barrier contraception during the entire study treatment period and through a minimum of 90 days after the last dose of study drug, or completely abstain from heterosexual intercourse. This must be done even if they are surgically sterilized (i.e., post-vasectomy).

4. Inability to provide informed consent.

5. Patient had myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see Appendix E), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening must be documented by the investigator as not medically relevant.

6. Known allergies to any of the components of the investigational treatment regimen.

7. Serious medical or psychiatric illness likely to interfere with participation in this clinical study.

8. Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial.

9. Prisoners

Related Conditions & MeSH terms

• Graft vs Host Disease
• Graft-versus-host Disease

Intervention

Drug:
• Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention
Cyclophosphamide 50 mg/kg IV over 2 hours on Day +3 and +4 Abatacept 10 mg/kg IV on days +5, +14, and +28 Tacrolimus 0.02 mg/kg IV by continuous infusion, starting on day +5. May switch to oral when tolerated, adjusted to maintain a drug level between 5-12ng/mL. Treatment is discontinued on day +60 after a 4 week-taper

Locations

Country	Name	City	State
United States	NYU Langone Health	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
NYU Langone Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Grade II-IV Acute GvHD by Day +120	The first day of grade II-IV acute GvHD will be used to calculate the cumulative incidence. The cumulative incidence will be defined as the percentage of participants with grade II-IV acute GvHD. The diagnosis of acute GvHD is based on clinical and pathological evaluation by the principal investigator in collaboration with the treating physician.; Overall Grades of Acute GvHD: 0 = none; = mild; = moderate; = severe; = life threatening	120 days
Secondary	Cumulative Incidence of Chronic GvHD	The first day of chronic GvHD will be used to calculate the cumulative incidence of chronic GvHD. This endpoint will be evaluated through day +365 post-transplant.	Day 365
Secondary	Cumulative Incidence of Primary Graft Failure	Graft failure is defined as failure to achieve neutrophil engraftment by day +28 or lack of donor chimerism > 50% by day 45, not due to the underlying malignancy.	Day 45
Secondary	Cumulative Incidence of Poor Graft Function	Poor Graft Function defined by at least 2 of the following 3 criteria: Hemoglobin < 8 g/dL, ANC < 0.5 x 109/L, and platelets < 20 x 109/L. The cytopenia must be unexplained (such as by disease relapse) and unresponsive to cytokines and must last at least 4 weeks.	Day 28
Secondary	Incidence of Secondary Graft Failure	Evaluated following engraftment through day +730. Secondary Graft Failure defined as poor graft function associated with donor chimerism < 5%.	Day 730
Secondary	Number of Treatment-Related Deaths	Number of participant deaths not attributable to disease relapse or progression. Will be evaluated to day +730.	Day 730
Secondary	Relapse Rate	Evaluated to day +730 and defined as the percentage of patients in whom the disease for which transplant is performed becomes evident by methods of disease detection after the transplant.	Day 730
Secondary	GvHD and Relapse-Free Survival (GRFS)	Evaluated to day +730 and defined as the percentage of participants who are without reported grade III-IV acute GvHD, without chronic GvHD requiring systemic therapy, and have not experienced relapse or death.	Day 730
Secondary	Overall Survival	Evaluated to day +730 and defined as percentage of participants alive at the end of the study's evaluation period.	Day 730